Apogee Therapeutics, Inc.
APGENasdaq
$134.00
↓ -0.1%Jul 17 close · end-of-day
Price
1Y↑ +249.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$9.3B
Enterprise Value
$8.3B
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$274.6M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
—
ROIC
—
Debt / Equity
—
Net Cash
$1.1B
Return 1Y
+243.6%
Company profile
We are a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Apogee Therapeutics, Inc. was incorporated under the laws of the State of Delaware on June 9, 2023. It had no business operations prior to this offering. We are a fully remote company and do not maintain physical corporate offices. Our employees work remotely from home. We maintain a mailing address at 221 Crescent St., Building 17, Suite 102b, Waltham, MA.
- CEO
- Michael Henderson
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- Massachusetts
- Website
- apogeetherapeutics.com
Management & directors
- Dambkowski CarlChief Medical Officer
- Henderson Michael ThomasChief Executive Officer
- Henderson JaneChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
APGE Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$1.06↑ +11.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$30.7M | -$93.0M | -$216.9M | -$285.6M |
| Net income | -$39.8M | -$84.0M | -$182.1M | -$255.8M |
| Diluted EPS | -$16.16 | -$3.36 | -$3.30 | -$4.22 |
| Operating cash flow | -$16.4M | -$74.8M | -$171.2M | -$227.4M |
| Free cash flow | — | -$74.9M | -$172.3M | -$232.6M |
| Gross margin | — | — | — | — |
| Operating margin | — | — | — | — |
| Net margin | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$44.1M | -$58.7M | -$75.9M | -$63.1M | -$73.2M | -$71.3M | -$78.1M | -$82.8M |
| Net income | -$33.8M | -$49.0M | -$67.2M | -$55.3M | -$66.1M | -$65.0M | -$69.4M | -$74.1M |
| Diluted EPS | -$0.60 | -$0.86 | -$1.20 | -$0.95 | -$1.13 | -$1.11 | -$1.03 | -$1.06 |
| Operating cash flow | -$29.3M | -$42.5M | -$67.7M | -$48.5M | -$62.0M | -$54.3M | -$62.7M | -$55.6M |
| Free cash flow | -$29.4M | -$43.3M | -$67.7M | -$52.8M | -$62.8M | -$54.3M | -$62.8M | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 20, 2026
Jul 12, 2026
Jul 10, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-14 | Dambkowski Carl· Chief Medical Officer | Gift | 8,000 | $0.00 | $0.00 | filing |
| 2026-07-10 | HENDERSON MICHAEL THOMAS· Chief Executive Officer | Gift | 75,046 | $0.00 | $0.00 | filing |
| 2026-07-08 | HENDERSON MICHAEL THOMAS· Chief Executive Officer | Sale | 20,000 | $133.63 | $2.7M | filing |
| 2026-07-01 | Dambkowski Carl· Chief Medical Officer | Sale | 5,500 | $132.74 | $730,070.00 | filing |
| 2026-07-01 | Dambkowski Carl· Chief Medical Officer | Option exercise | 4,125 | $22.86 | $94,297.50 | filing |
| 2026-06-22 | HENDERSON MICHAEL THOMAS· Chief Executive Officer | Sale | 80,000 | $132.54 | $10.6M | filing |
| 2026-06-22 | Dambkowski Carl· Chief Medical Officer | Sale | 26,400 | $132.60 | $3.5M | filing |
| 2026-06-10 | HENDERSON MICHAEL THOMAS· Chief Executive Officer | Sale | 7,654 | $82.78 | $633,598.12 | filing |
| 2026-06-10 | HENDERSON MICHAEL THOMAS· Chief Executive Officer | Sale | 6,770 | $82.21 | $556,561.70 | filing |
| 2026-06-10 | HENDERSON MICHAEL THOMAS· Chief Executive Officer | Sale | 2,305 | $86.27 | $198,852.35 | filing |
| 2026-06-10 | HENDERSON MICHAEL THOMAS· Chief Executive Officer | Sale | 1,577 | $85.19 | $134,344.63 | filing |
| 2026-06-10 | HENDERSON MICHAEL THOMAS· Chief Executive Officer | Sale | 1,080 | $84.18 | $90,914.40 | filing |
| 2026-06-10 | HENDERSON MICHAEL THOMAS· Chief Executive Officer | Sale | 614 | $86.89 | $53,350.46 | filing |
| 2026-06-03 | Dambkowski Carl· Chief Medical Officer | Sale | 5,500 | $78.71 | $432,905.00 | filing |
| 2026-06-03 | Dambkowski Carl· Chief Medical Officer | Option exercise | 4,125 | $22.86 | $94,297.50 | filing |
| 2026-05-13 | HENDERSON MICHAEL THOMAS· Chief Executive Officer | Sale | 18,659 | $82.05 | $1.5M | filing |
| 2026-05-13 | HENDERSON MICHAEL THOMAS· Chief Executive Officer | Sale | 1,341 | $82.58 | $110,739.78 | filing |
| 2026-05-06 | Dambkowski Carl· Chief Medical Officer | Sale | 3,700 | $83.92 | $310,504.00 | filing |
| 2026-05-06 | Dambkowski Carl· Chief Medical Officer | Sale | 1,800 | $84.60 | $152,280.00 | filing |
| 2026-05-06 | Dambkowski Carl· Chief Medical Officer | Option exercise | 4,125 | $22.86 | $94,297.50 | filing |
| 2026-05-01 | Henderson Jane· Chief Financial Officer | Sale | 900 | $82.60 | $74,340.00 | filing |
| 2026-05-01 | Henderson Jane· Chief Financial Officer | Sale | 811 | $81.02 | $65,707.22 | filing |
| 2026-05-01 | Henderson Jane· Chief Financial Officer | Sale | 289 | $83.16 | $24,033.24 | filing |
| 2026-04-16 | Henderson Jane· Chief Financial Officer | Sale | 2,000 | $90.00 | $180,000.00 | filing |
| 2026-04-16 | HENDERSON MICHAEL THOMAS· Chief Executive Officer | Option exercise | 3,000 | $22.86 | $68,580.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.